Why the study?
Cardiomyocyte atrophy's contribution to left ventricular mass loss in doxorubicin-induced cardiotoxicity is underestimated and its underlying mechanisms remain poorly understood.
This review highlights cardiomyocyte atrophy as a key mechanism in doxorubicin-induced cardiotoxicity, distinct from cell death, and identifies potential therapeutic targets including FOXO, TRPC3-Nox2, and PI3K pathways.
Answers are grounded in this paper and cite their sources.
CMA in doxorubicin cardiotoxicity remains understudied relative to cell death; leaves open mechanistic targets and translational relevance.
Left ventricular (LV) mass loss is prevalent in doxorubicin (DOX)-induced cardiotoxicity and is responsible for the progressive decline of cardiac function. Comparing with the well-studied role of cell death, the part of cardiomyocyte atrophy (CMA) playing in the LV mass loss is underestimated and the knowledge of the underlying mechanism is still limited. In this review, we summarized the recent advances in the DOX-induced CMA. We found that the CMA caused by DOX is associated with the upregulation of FOXOs and "atrogenes," the activation of transient receptor potential canonical 3-NADPH oxidase 2 (TRPC3-Nox2) axis, and the suppression of IGF-1-PI3K signaling pathway. The imbalance of anabolic and catabolic process may be the common final pathway of these mechanisms. At last, we provided some strategies that have been demonstrated to alleviate the DOX-induced CMA in animal models.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: